SCHEMBL5327434

SCHEMBL5327434

O=C(C(=O)n1cccc1)n1cccc1

nearest known ligand 0.38

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
FBP1 P09467 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL525220 0.85 FBP1 (0.38) FBP1
SCHEMBL7126113 0.85 FBP1 (0.38) FBP1
SCHEMBL11201007 0.83 FBP1 (0.33) FBP1
SCHEMBL5609915 0.81 TSHR (0.33) FBP1
SCHEMBL5609875 0.81 FBP1 (0.32) FBP1
SCHEMBL12667290 0.77 FAAH (0.41)
SCHEMBL5154971 0.76 TDP1 (0.35)
SCHEMBL3239691 0.74
SCHEMBL1333409 0.74
SCHEMBL3251574 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102241672-A 2,3-dipyrrolyl-6-acylaminoquinoxaline compounds and preparation method thereof UNIVTAISHAN MEDICAL 2011-11-16 CN disclosed
WO-2007121853-A3 LIGHTENING AND/OR COLOURING AGENTS COMPRISING N,N'-OXALYLDIAZOLES AND/OR OXIMIDYLDIAZOLES HENKEL KGAA (DE) 2007-12-21 WO disclosed
WO-2007121853-A2 LIGHTENING AND/OR COLOURING AGENTS COMPRISING N,N'-OXALYLDIAZOLES AND/OR OXIMIDYLDIAZOLES HENKEL AG & CO. KGAA (DE) 2007-11-01 WO disclosed
WO-2007121853-A2 LIGHTENING AND/OR COLOURING AGENTS COMPRISING N,N'-OXALYLDIAZOLES AND/OR OXIMIDYLDIAZOLES HENKEL AG & CO. KGAA (DE) 2007-11-01 WO disclosed
US-20030162960-A1 Colormetric sensor compositions and methods NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-08-28 US disclosed
US-6482949-B1 Colormetric sensor compositions and methods NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2002-11-19 US disclosed
US-5221680-A Controlling or prevention of diseases of the cardiovascular system CASSELLA AKTIENGESELLSCHAFT (DE) 1993-06-22 US disclosed
EP-0429751-B1 SUBSTITUTED 3-AMINO-SYDNONIMINES, PROCESS FOR THEIR PREPARATION AND THEIR USE CASSELLA Aktiengesellschaft (DE) 1993-06-16 EP disclosed
EP-0346694-B1 SUBSTITUTED 3-AMINOSYDNONE IMINES, PROCESS FOR THEIR PREPARATION AND THEIR USE CASSELLA Aktiengesellschaft (DE) 1993-01-27 EP disclosed
US-5179206-A Cardiovascular disorders; angina pectoris; hypotensive agents CASSELLA AKTIENGELLSCHAFT (DE) 1993-01-12 US disclosed
EP-0327808-B1 SUBSTITUTED 3-AMINOSYDNONIMINES, PROCESS FOR THEIR PREPARATION AND THEIR USE CASSELLA Aktiengesellschaft (DE) 1991-05-02 EP disclosed
US-5006540-A Cardiotonic agents CASSELLA AKTIENGESELLSCHAFT (DE) 1991-04-09 US disclosed
EP-0406659-A1 Substituted 3-aminosydnonimines, process for their preparation and their use CASSELLA Aktiengesellschaft (DE) 1991-01-09 EP disclosed
EP-0406661-A1 Substituted 3-aminosydnonimines, process for their preparation, and their use CASSELLA Aktiengesellschaft (DE) 1991-01-09 EP disclosed
US-4937244-A HYPOTENSIVE AND CARDIOTONIC AGENTS; ANGINA PECTORIS CASSELLA AKTIENGESELLSCHAFT (DE) 1990-06-26 US disclosed
EP-0367036-A2 Substituted 3-aminosydnonimines, process for their preparation and their use CASSELLA Aktiengesellschaft (DE) 1990-05-09 EP disclosed
EP-0346684-A1 Substituted 3-aminosydnonimines, method for their preparation and their use CASSELLA Aktiengesellschaft (DE) 1989-12-20 EP disclosed
EP-0346694-A1 Substituted 3-Aminosydnone imines, process for their preparation and their use CASSELLA Aktiengesellschaft (DE) 1989-12-20 EP disclosed
EP-0327808-A1 Substituted 3-aminosydnonimines, process for their preparation and their use CASSELLA Aktiengesellschaft (DE) 1989-08-16 EP disclosed
EP-0312773-A2 Substituted 3-aminosydnonimines, process for their preparation and their use CASSELLA Aktiengesellschaft (DE) 1989-04-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162960-A1 Colormetric sensor compositions and methods PAH, NISCH, SPR FBP1 2602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.